Literature DB >> 21837709

Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart.

Andrea Y Angstadt1, Alison Motsinger-Reif, Rachael Thomas, William C Kisseberth, C Guillermo Couto, Dawn L Duval, Dahlia M Nielsen, Jaime F Modiano, Matthew Breen.   

Abstract

Osteosarcoma (OS) is the most commonly diagnosed malignant bone tumor in humans and dogs, characterized in both species by extremely complex karyotypes exhibiting high frequencies of genomic imbalance. Evaluation of genomic signatures in human OS using array comparative genomic hybridization (aCGH) has assisted in uncovering genetic mechanisms that result in disease phenotype. Previous low-resolution (10-20 Mb) aCGH analysis of canine OS identified a wide range of recurrent DNA copy number aberrations, indicating extensive genomic instability. In this study, we profiled 123 canine OS tumors by 1 Mb-resolution aCGH to generate a dataset for direct comparison with current data for human OS, concluding that several high frequency aberrations in canine and human OS are orthologous. To ensure complete coverage of gene annotation, we identified the human refseq genes that map to these orthologous aberrant dog regions and found several candidate genes warranting evaluation for OS involvement. Specifically, subsequenct FISH and qRT-PCR analysis of RUNX2, TUSC3, and PTEN indicated that expression levels correlated with genomic copy number status, showcasing RUNX2 as an OS associated gene and TUSC3 as a possible tumor suppressor candidate. Together these data demonstrate the ability of genomic comparative oncology to identify genetic abberations which may be important for OS progression. Large scale screening of genomic imbalance in canine OS further validates the use of the dog as a suitable model for human cancers, supporting the idea that dysregulation discovered in canine cancers will provide an avenue for complementary study in human counterparts.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837709     DOI: 10.1002/gcc.20908

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  37 in total

1.  Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray.

Authors:  Duncan S Russell; Lauren Jaworski; William C Kisseberth
Journal:  J Vet Diagn Invest       Date:  2018-04-09       Impact factor: 1.279

2.  Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing.

Authors:  Sunetra Das; Rupa Idate; Kathryn E Cronise; Daniel L Gustafson; Dawn L Duval
Journal:  Mol Cancer Ther       Date:  2019-06-07       Impact factor: 6.261

3.  Targeting osteosarcoma.

Authors:  Darien E Reed; Kevan M Shokat
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

4.  Anchoring the dog to its relatives reveals new evolutionary breakpoints across 11 species of the Canidae and provides new clues for the role of B chromosomes.

Authors:  Shannon E Duke Becker; Rachael Thomas; Vladimir A Trifonov; Robert K Wayne; Alexander S Graphodatsky; Matthew Breen
Journal:  Chromosome Res       Date:  2011-09-27       Impact factor: 5.239

Review 5.  Domestic dogs and cancer research: a breed-based genomics approach.

Authors:  Brian W Davis; Elaine A Ostrander
Journal:  ILAR J       Date:  2014

6.  The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine.

Authors:  J S Fowles; D D Dailey; D L Gustafson; D H Thamm; D L Duval
Journal:  Vet Comp Oncol       Date:  2016-05-19       Impact factor: 2.613

Review 7.  Advancing therapy for osteosarcoma.

Authors:  Jonathan Gill; Richard Gorlick
Journal:  Nat Rev Clin Oncol       Date:  2021-06-15       Impact factor: 66.675

8.  Canine osteosarcoma cell lines from patients with differing serum alkaline phosphatase concentrations display no behavioural differences in vitro.

Authors:  K E Holmes; V Thompson; C M Piskun; R A Kohnken; M K Huelsmeyer; T M Fan; T J Stein
Journal:  Vet Comp Oncol       Date:  2013-03-12       Impact factor: 2.613

Review 9.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

10.  Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.

Authors:  Qian Yin; Li Tang; Kaimin Cai; Rong Tong; Rachel Sternberg; Xujuan Yang; Lawrence W Dobrucki; Luke B Borst; Debra Kamstock; Ziyuan Song; William G Helferich; Jianjun Cheng; Timothy M Fan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.